SCHEMBL3963612

SCHEMBL3963612

CCOC(=O)c1cc2ccccc2n1CCc1cccc(OC)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.59
KDM4E B2RXH2 1/20 0.59
CRHBP P24387 1/20 0.59
CRHR2 Q13324 1/20 0.59
NOD2 Q9HC29 3/20 0.58
NOD1 Q9Y239 3/20 0.58
F10 P00742 3/20 0.56
KMT2A Q03164 2/20 0.56
MEN1 O00255 1/20 0.56
MTNR1A P48039 1/20 0.49
MTNR1B P49286 1/20 0.49
MAPT P10636 2/20 0.47
CCR2 P41597 1/20 0.47
TSHR P16473 1/20 0.46
TSPO P30536 1/20 0.46
ABCG2 Q9UNQ0 1/20 0.45
TP53 P04637 1/20 0.45
THRB P10828 1/20 0.45
ELANE P08246 1/20 0.45
SRC P12931 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8686408 0.87 SMN1; SMN2 (0.68) SMN1; SMN2KDM4ECRHBPCRHR2NOD2
SCHEMBL3960264 0.86 CCR2 (0.61) F10KMT2ACCR2ABCG2SIGMAR1
SCHEMBL6858374 0.81 NOD2 (0.80) SMN1; SMN2KDM4ECRHBPCRHR2NOD2
SCHEMBL3962292 0.81 NOD2 (0.69) SMN1; SMN2KDM4ECRHBPCRHR2NOD2
SCHEMBL6752352 0.80 KDM4E (0.71) SMN1; SMN2KDM4ECRHBPCRHR2NOD2
SCHEMBL4798323 0.78 NOD2 (0.85) SMN1; SMN2KDM4ECRHBPCRHR2NOD2
SCHEMBL18322286 0.78 KDM4E (0.73) SMN1; SMN2KDM4ECRHBPCRHR2NOD2
SCHEMBL30489155 0.78 KDM4E (0.73) SMN1; SMN2KDM4ECRHBPCRHR2NOD2
SCHEMBL4215637 0.78 KDM4E (0.70) SMN1; SMN2KDM4ECRHBPCRHR2NOD2
SCHEMBL13742183 0.78 KDM4E (0.70) SMN1; SMN2KDM4ECRHBPCRHR2NOD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1451185-B1 INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS SANOFI AVENTIS DEUTSCHLAND (DE) 2014-08-06 EP disclosed
US-20090069565-A1 NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-03-12 US disclosed
US-6906084-B2 Indole derivatives as factor Xa inhibitors AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-06-14 US disclosed
US-20050043302-A1 New indole derivatives as factor Xa inhibitors AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2005-02-24 US disclosed
EP-1451185-A1 INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS Aventis Pharma Deutschland GmbH (DE) 2004-09-01 EP disclosed
US-20030199689-A1 New indole derivatives as factor Xa inhibitors SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2003-10-23 US disclosed
WO-2003044014-A1 INDOLE-2-CARBOXAMIDES AS FACTOR XA INHIBITORS AVENTIS PHARMA DEUTSCHLAND GMBH (DE) 2003-05-30 WO disclosed
EP-1314733-A1 Indole-2-carboxamides as factor Xa inhibitors Aventis Pharma Deutschland GmbH (DE) 2003-05-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069565-A1 NEW INDOLE DERIVATIVES AS FACTOR XA INHIBITORS F12, F5, F2 SMN1; SMN2 4130/4885KDM4E 1568/4885CRHBP 4559/4885
US-20030199689-A1 New indole derivatives as factor Xa inhibitors F5, F12, F2 SMN1; SMN2 4319/4885KDM4E 1206/4885CRHBP 4454/4885
US-20050043302-A1 New indole derivatives as factor Xa inhibitors F12, F5, F2 SMN1; SMN2 4060/4885KDM4E 1584/4885CRHBP 4655/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.